JPMorgan analyst Lisa Gill raised the firm’s price target on Privia Health (PRVA) to $33 from $32 and keeps an Overweight rating on the shares. The firm updated the company’s estimates post earnings.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRVA:
- BMO Capital Highlights Privia Health Group’s Strong Growth Potential and Differentiated Risk Management in Value-Based Care
- Privia Health initiated with an Outperform at BMO Capital
- Privia Health price target raised to $34 from $32 at Canaccord
- Privia Health price target raised to $23 from $22 at Barclays
- Privia Health’s Earnings Call Highlights Robust Growth